Illumina Stock News

RBC Capital Markets Equity Research Analyst Conor McNamara joins Yahoo Finance Live to discuss the proxy battle between Illumina and activist investor Carl Ichan, risks of closing the GRAIL acquisitio

The decision reverses an administrative judge's ruling that dismissed the FTC's initial challenge of Illumina's $7.1 billion Grail deal.

The agency said the combination would hurt competition for cancer-detection tests while raising prices.

Activist investor Carl Icahn ramped up his proxy fight against Illumina with a blistering statement.

The entire stock market is gearing up for a major breakout as investors are becoming convinced that the banking sector has stabilized and that the Federal Reserve is, at the very least, almost done hi

Illumina's (ILMN) Connected Software is an end-to-end software system that standardizes analysis tools and connects data across the genomics workflow.

Icahn said Illumina should bring back former CEO Jay Flatley, saying current management is making the mistake of holding onto the $7.1 billion Grail deal.

Illumina Inc. ILMN activist shareholder and billionaire Carl Icahn told The Wall Street Journal he'd like to see the return of ex-CEO Jay Flatley to replace the gene sequencing device maker's current

The billionaire activist, who has launched a proxy battle at Illumina, wants change at the management level too, and he has a candidate in mind for the top spot: former CEO Jay Flatley.

Icahn, who owns a 1.4% stake in Illumina, began his latest proxy battle on March 13, criticizing management for pursuing the 2021 Grail deal amidst regulatory scrutiny.

Illumina is still facing issues around its GRAIL acquisition. The company has seen continued uncertainty and has incurred a lot of losses with the GRAIL acquisition while the core business was perform

Carl Icahn claims Illumina directors demanded extra personal liability insurance before the biotech company signed off on a $7.1 billion acquisition of Grail

Analysts at Canaccord Genuity (TSX:CF, LSE:CF) have reiterated their ‘Buy' rating for Illumina Inc (NASDAQ:ILMN) following recent activism efforts against the biotechnology company led by veteran ac

Healthcare costs in America and the world are set to rise in the foreseeable future. All thanks to an aging population, and the expectation that healthcare companies will be able to cure more of our d

A fight has broken out between veteran activist Carl Icahn and biotech company Illumina as the investor nominates three candidates to the board.